Search results for "EPS"

showing 10 items of 1777 documents

Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression

2020

Sepsis is a life-threatening condition that occurs when the body responds to an infection damaging its own tissues. Sepsis survivors sometimes suffer from immunosuppression increasing the risk of death. To our best knowledge, there is no ‘gold standard’ for defining immunosuppression except for a composite clinical end point. As the immune system is exposed to epigenetic changes during and after sepsis, research that focuses on identifying new biomarkers to detect septic patients with immunoparalysis could offer new epigenetic-based strategies to predict short- and long-term pathological events related to this life-threatening state. This review describes the most relevant epigenetic mecha…

0301 basic medicineCancer ResearchRNA Untranslatedmedicine.medical_treatmentAdaptive ImmunityBiologyBioinformaticsEpigenesis GeneticHistonesSepsis03 medical and health sciences0302 clinical medicineImmune systemSepsismicroRNAGeneticsmedicineHumansEpigeneticsPathologicalImmunosuppression TherapyEpigenetic biomarkersSeptic shockImmunosuppressionDNA Methylationmedicine.diseaseShock SepticImmunity Innate030104 developmental biology030220 oncology & carcinogenesisBiomarkersEpigenomics
researchProduct

Acute surgical abdomen during the COVID‑19 pandemic: Clinical and therapeutic challenges

2021

The present study investigated the effects of the COVID-19 pandemic on the clinical presentation and therapeutic management of acute surgical abdomen. A retrospective study of emergency hospitalizations with a diagnosis of acute surgical abdomen between April and July 2020 vs. a similar period in 2019 was performed. The observation sheets and the operating protocols were analyzed. Between April and July 2020, 50 cases of acute surgical abdomen were hospitalized and treated, compared to 43 cases in the same period last year. The main types of pathology in both groups included: Occlusions (60%, respectively 44.2% in 2019) and peritonitis (32%, respectively 41.8% in 2019). There was an increas…

0301 basic medicineCancer Researchmedicine.medical_specialtyAbdominal painbusiness.industryGeneral surgeryPerforation (oil well)PeritonitisRetrospective cohort studyArticlesGeneral Medicinemedicine.diseaseAsepsis03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmunology and Microbiology (miscellaneous)Acute abdomen030220 oncology & carcinogenesisPandemicmedicineAbdomenmedicine.symptombusinessExperimental and Therapeutic Medicine
researchProduct

Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?

2016

Background Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. Methods Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in the…

0301 basic medicineCandida spp; Invasive fungal infections; Sepsismedicine.medical_specialtyAntifungal AgentsSepsi030106 microbiologyMycoseSubgroup analysisCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicineInvasive fungal infectionRandomized controlled trialRisk FactorsInvasive fungal infectionslawSepsisIntensive caremedicineHumansAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineCandidaCandida sppProphylaxisbusiness.industryIncidence (epidemiology)Risk FactorCandidiasismedicine.diseaseConfidence intervalCritical careFungalMycosesRelative riskCandida sppCandidiasiCandida spp; Invasive fungal infections; Sepsis; Antifungal Agents; Candida; Humans; Risk Factors; Candidiasis; Mycoses; Critical Care and Intensive Care MedicineInvasive fungal diseasebusinessResearch ArticleHuman
researchProduct

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resi…

2020

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until February 12th, 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies publish…

0301 basic medicineCarbapenem-resistant enterobacteriaceaeBiochemistrylaw.inventionsepsisCeftazidime‐avibactam0302 clinical medicineRandomized controlled trialsystematic reviewlawPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsnetwork meta-analysisceftazidime-avibactamAnti‐infective agentnetwork meta-analysiInfectious Diseasescarbapenem-resistant EnterobacteriaceaeMeta-analysisβ-lactamase inhibitors.sepsimedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapyβ-lactamase inhibitors030106 microbiologyMEDLINEβ‐lactamase inhibitorsMicrobiologyArticle03 medical and health sciencesCarbapenem‐resistant Enterobacteriaceaemultidrug resistanceInternal medicinemedicineanti-infective agentbacteremiabusiness.industrylcsh:RM1-950Retrospective cohort studyCeftazidime/avibactammedicine.diseaseinfectionlcsh:Therapeutics. PharmacologyBacteremiaanti-infective agentsbusinessNetwork meta‐analysi
researchProduct

Are mutations in the dhrs9 gene causally linked to epilepsy? A case report

2020

The DHRS9 gene is involved in several pathways including the synthesis of allopregnanolone from progesterone. Allopregnanolone is a positive modulator of gamma aminobutyric acid (GABA) action and plays a role in the control of neuronal excitability and seizures. Whole-exome sequencing performed on a girl with an early onset epilepsy revealed that she was a compound heterozygote for two novel missense mutations of the DHRS9 gene likely to disrupt protein function. No previous studies have reported the implication of this gene in epilepsy. We discuss a new potential pathogenic mechanism underlying epilepsy in a child, due to a defective progesterone pathway.

0301 basic medicineCase ReportCompound heterozygosityBioinformaticsAllopregnanolone DHRS9 Exome GABA NGS Temporal lobe epilepsygamma-Aminobutyric acid03 medical and health scienceschemistry.chemical_compoundEpilepsyGABA0302 clinical medicinemedicineMissense mutationGeneExomelcsh:R5-920business.industryMechanism (biology)DHRS9AllopregnanoloneallopregnanoloneGeneral Medicinetemporal lobe epilepsymedicine.disease030104 developmental biologychemistryNGSlcsh:Medicine (General)business030217 neurology & neurosurgeryexomemedicine.drug
researchProduct

Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs)

2017

This paper describes the development of a class of peptide-based inhibitors as novel antitrypanosomal and antimalarial agents. The inhibitors are based on a characteristic peptide sequence for the inhibition of the cysteine proteases rhodesain of Trypanosoma brucei rhodesiense and falcipain-2 of Plasmodium falciparum. We exploited the reactivity of novel unsaturated electrophilic functions such as vinyl-sulfones, -ketones, -esters, and -nitriles. The Michael acceptors inhibited both rhodesain and falcipain-2, at nanomolar and micromolar levels, respectively. In particular, the vinyl ketone 3b has emerged as a potent rhodesain inhibitor (k2nd = 67 × 106 M-1 min-1), endowed with a picomolar b…

0301 basic medicineCathepsin LAntimalarialPeptideHeLa Cell01 natural sciencesCysteine Proteinase InhibitorDipeptideDrug DiscoveryPeptide sequencechemistry.chemical_classificationTrypanocidal AgentbiologyNeglected DiseasesStereoisomerismDipeptidesTrypanocidal AgentsMAJOR CYSTEINE PROTEASE PLASMODIUM-FALCIPARUM TRYPANOSOMA-BRUCEI CONFORMATIONAL-ANALYSIS BIOLOGICAL EVALUATION HIGHLY POTENT VINYL-ESTER INHIBITORS PEPTIDOMIMETICS SUBSTRATEMolecular Docking SimulationCysteine EndopeptidasesBiochemistryMolecular MedicineHumanProteasesNeglected DiseaseStereochemistryPhenylalaninePlasmodium falciparumTrypanosoma brucei bruceiCysteine Proteinase InhibitorsMolecular Dynamics SimulationTrypanosoma bruceiAntimalarialsStructure-Activity Relationship03 medical and health sciencesparasitic diseasesHumansStructure–activity relationship010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceHydrogen BondingTrypanosoma brucei rhodesiensePlasmodium falciparumbiology.organism_classificationMalaria0104 chemical sciencesTrypanosomiasis African030104 developmental biologychemistryCarbamateCarbamatesCysteine EndopeptidaseHeLa CellsCysteineJournal of Medicinal Chemistry
researchProduct

Beauvericin and enniatin B effects on a human lymphoblastoid Jurkat T-cell model

2018

Abstract Several mycotoxins exert their effect on the immunological system; some are classified as immunotoxic. Jurkat T-cells were used to study toxic effects of beauvericin (BEA) and enniatin B (ENN B). Both are not legislated mycotoxins with increasing presence in feed and food. Concentrations studied were from 1 to 15 μM at 24, 48 and 72 h. Cell death by increasing the percentage of apoptotic/necrotic cells was: BEA > ENN B. IC50 values ranged from 3 to 7.5 μM for BEA. ENN B 15 μM decreased viability (21-29%). The percentage of apoptotic/necrotic cells was BEA > ENN B at 24 h but not at 48 h. Caspase-3&7 activation profile varied, although both mycotoxins increased this activation. No d…

0301 basic medicineCell SurvivalT-LymphocytesT cellApoptosisToxicologyJurkat cells03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyDepsipeptidesmedicineHumansMycotoxinCytotoxicityCaspase 7Caspase 3LymphoblastCell Cycle04 agricultural and veterinary sciencesGeneral MedicineMycotoxins040401 food scienceMolecular biologyBeauvericin030104 developmental biologymedicine.anatomical_structurechemistryApoptosisToxicityFood ScienceFood and Chemical Toxicology
researchProduct

Enniatin B induces expression changes in the electron transport chain pathway related genes in lymphoblastic T-cell line

2018

Abstract Enniatin B is a ionophoric and lipophilic mycotoxin which reaches the bloodstream and has the ability to penetrate into cellular membranes. The purpose of this study was to reveal changes in the gene expression profile caused by enniatin B in human Jurkat lymphoblastic T-cells after 24 h of exposure at 1.5, 3 and 5 μM by next generation sequencing. It was found that up to 27% of human genome expression levels were significantly altered (5750 genes for both down-regulation and up-regulation). In the three enniatin B concentrations studied 245 differentially expressed genes were found to be overlapped, 83 were down and 162 up-regulated. ConsensusPathDB analysis of over-representation…

0301 basic medicineCellular respirationT-LymphocytesDown-RegulationMitochondrionToxicologyJurkat cellsTranscriptomeJurkat Cells03 medical and health sciences0404 agricultural biotechnologyDepsipeptidesGene expressionHumansGeneChemistryRespiratory chain complexNucleoside monophosphate metabolic process04 agricultural and veterinary sciencesGeneral MedicinePrecursor Cell Lymphoblastic Leukemia-Lymphoma040401 food scienceUp-RegulationCell biologyGene Expression Regulation Neoplastic030104 developmental biologyElectron Transport Chain Complex ProteinsTranscriptomeFood ScienceFood and Chemical Toxicology
researchProduct

Molecular Mechanism Involved in the Pathogenesis of Early-Onset Epileptic Encephalopathy

2019

Recent studies have shown that neurologic inflammation may both precipitate and sustain seizures, suggesting that inflammation may be involved not only in epileptogenesis but also in determining the drug-resistant profile. Extensive literature data during these last years have identified a number of inflammatory markers involved in these processes of “neuroimmunoinflammation” in epilepsy, with key roles for pro-inflammatory cytokines such as: IL-6, IL-17 and IL-17 Receptor (IL-17R) axis, Tumor-Necrosis-Factor Alpha (TNF-α) and Transforming-Growth-Factor Beta (TGF-β), all responsible for the induction of processes of blood-brain barrier (BBB) disruption and inflammation of the Central Nervou…

0301 basic medicineCentral nervous systemInflammationContext (language use)ReviewEpileptogenesisNOlcsh:RC321-571pathogenic mechanismsPathogenesis03 medical and health sciencesCellular and Molecular NeuroscienceEpilepsy0302 clinical medicineImmune systemMedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMolecular BiologyPathologicalchildhoodbusiness.industrybiological markermedicine.diseaseepileptic encephalopathy030104 developmental biologymedicine.anatomical_structureinflammationmedicine.symptombusinessNeurosciencebiological markers030217 neurology & neurosurgeryNeurosciencebiological markers epileptic encephalopathy inflammation pathogenic mechanisms childhoodFrontiers in Molecular Neuroscience
researchProduct

Identification of Protein Complexes Associated with the Usher Syndrome 2C and Epilepsy-Associated Protein VLGR1 Applying Affinity Proteomics

2017

Authors aimed to identify novel VLGR1-associated protein networks to shed light on its integration into signaling pathways and the cellular compartments in which VLGR1 functions using high-resolution affinity proteomics based on tandem affinity purifications (TAPs).

0301 basic medicineChemistryUsher syndromeGenomics02 engineering and technologyComputational biology021001 nanoscience & nanotechnologymedicine.diseaseProteomics03 medical and health sciencesEpilepsy030104 developmental biologymedicineIdentification (biology)Signal transduction0210 nano-technologyProtein networkCellular compartmentGenomics and Computational Biology
researchProduct